Home Physical Sciences Crystal structure of 3-((2,4-dichlorobenzyl)thio)-5-methyl-7-(trifluoromethyl)-[1,2,4]triazolo [4,3-c]pyrimidine, C14H9Cl2F3N4S
Article Open Access

Crystal structure of 3-((2,4-dichlorobenzyl)thio)-5-methyl-7-(trifluoromethyl)-[1,2,4]triazolo [4,3-c]pyrimidine, C14H9Cl2F3N4S

  • , , , ORCID logo EMAIL logo and ORCID logo
Published/Copyright: August 30, 2022

Abstract

C14H9Cl2F3N4S, monoclinic, P21/c (no. 14), a = 11.6567(3) Å, b = 4.80480(10) Å, c = 28.1051(7) Å, β = 101.336(2)°, V = 1543.40(6) Å3, Z = 4, Rgt (F) = 0.0358, wRref (F 2) = 0.1014, T = 250 K.

CCDC no.: 2189490

The molecular structure is shown in the figure. Table 1 contains crystallographic data and Table 2 contains the list of the atoms including atomic coordinates and displacement parameters.

Table 1:

Data collection and handling.

Crystal: Colourless block
Size: 0.15 × 0.12 × 0.10 mm
Wavelength: Cu Kα radiation (1.54184 Å)
μ: 5.42 mm−1
Diffractometer, scan mode: XtaLAB AFC12 (RINC), ω
θ max, completeness: 71.5°, >99%
N(hkl)measured, N(hkl)unique, R int: 6825, 2942, 0.029
Criterion for I obs, N(hkl)gt: I obs > 2 σ(I obs), 2732
N(param)refined: 218
Programs: Olex2 [1], SHELX [2, 3]
Table 2:

Fractional atomic coordinates and isotropic or equivalent isotropic displacement parameters (Å2).

Atom x y z U iso*/U eq
Cl1 0.61526 (4) 0.91205 (11) 0.25194 (2) 0.04251 (15)
Cl2 0.96208 (5) 0.16952 (11) 0.29198 (2) 0.05383 (18)
S1 0.47856 (4) 0.86987 (9) 0.34993 (2) 0.03316 (14)
F1 0.06162 (11) −0.0779 (3) 0.43520 (5) 0.0580 (3)
F2 0.07412 (13) 0.2490 (3) 0.48675 (6) 0.0679 (4)
F3 0.17998 (12) −0.1150 (4) 0.50342 (6) 0.0727 (5)
N1 0.57288 (12) 0.5267 (3) 0.42441 (5) 0.0345 (3)
N2 0.53931 (12) 0.3321 (3) 0.45531 (5) 0.0347 (3)
N3 0.38007 (11) 0.4969 (3) 0.40633 (5) 0.0261 (3)
N4 0.18782 (12) 0.3698 (3) 0.40823 (5) 0.0329 (3)
C1 0.71388 (14) 0.7660 (4) 0.34453 (6) 0.0308 (4)
C2 0.71210 (14) 0.7250 (4) 0.29528 (6) 0.0309 (4)
C3 0.78759 (15) 0.5421 (4) 0.27899 (7) 0.0350 (4)
H3 0.783762 0.515206 0.245948 0.042*
C4 0.86860 (15) 0.4006 (4) 0.31271 (7) 0.0364 (4)
C5 0.87542 (16) 0.4398 (4) 0.36197 (7) 0.0405 (4)
H5 0.931283 0.345984 0.384463 0.049*
C6 0.79785 (16) 0.6205 (4) 0.37710 (7) 0.0382 (4)
H6 0.801876 0.645854 0.410192 0.046*
C7 0.63305 (15) 0.9672 (4) 0.36217 (7) 0.0357 (4)
H7A 0.640508 1.146722 0.347290 0.043*
H7B 0.658683 0.989547 0.396935 0.043*
C8 0.47907 (14) 0.6222 (3) 0.39548 (6) 0.0281 (3)
C9 0.42479 (15) 0.3169 (4) 0.44444 (6) 0.0288 (3)
C10 0.34531 (15) 0.1605 (4) 0.46578 (6) 0.0324 (4)
H10 0.370576 0.037512 0.491236 0.039*
C11 0.23138 (15) 0.1999 (4) 0.44718 (6) 0.0322 (4)
C12 0.13620 (17) 0.0626 (4) 0.46843 (7) 0.0409 (4)
C13 0.21438 (16) 0.6926 (4) 0.34560 (7) 0.0384 (4)
H13A 0.235632 0.882540 0.353452 0.058*
H13B 0.130731 0.677257 0.337164 0.058*
H13C 0.247868 0.634035 0.318649 0.058*
C14 0.25922 (13) 0.5126 (4) 0.38831 (6) 0.0286 (3)

Source of material

The mixture of 2-methyl-4-chloro-6-trifluoromethylpyrimidine (20 mmol) and hydrazine hydrate (30 mmol) was stirred in an ice bath in absolute ethanol (50 mL). Until the reaction completed, water was added to the system to obtain a yellow solid. Column chromatography was used to purify the residue to get a pale yellow solid. Then a mixture of the pale yellow solid (50 mmol), carbon disulfide (75 mmol) and triethylamine (75 mmol) were refluxed in anhydrous ethanol for 3 h. Then the system was cooled to room temperature, and 2,4-dichlorobenzyl chloride was added. After completion, the solvent was removed to get the residue, which was purified by column chromatography. Needle colorless crystals were obtained through cooling the ethanol solution of the target compound.

Experimental details

A suitable crystal was selected and tested on a XtaLAB AFC12 (RINC): Kappa single diffractometer. Using Olex2 [1], the structure was solved with the SHELXT [2] structure solution program using Intrinsic Phasing and refined with the SHELXL [3] refinement package using Least Squares minimisation.

Comment

Fused pyrimidine containing systems possess extensive biological activities [4], [5], [6], [7], [8], [9] and were widely applied in medicine [10] and as pesticides [11]. This study aims to develop pyrimidine derivatives with new structures and good bioactivities. The target compound is shown in the figure. The N–N bond distance is 1.384(2) Å. The C–S bond lengths are 1.8266(18) and 1.7468(17) Å respectively. The C–Cl bond lengths are 1.7394(18) and 1.7347(18) Å. In addition, the characteristic C–S–C bond angle is 100.09(8)°. All geometric parameters are in expected ranges [12].


Corresponding author: Qiang Fei, Food and Pharmaceutical Engineering Institute, Guiyang University, Guiyang, Guizhou, China, E-mail:

Funding source: Science and Technology Fund Project of Guizhou

Award Identifier / Grant number: [2020]1Z023; NO. QKHJC[2019]1015

Funding source: Guizhou Provincial Department of Education Youth Science and Technology Talents Growth Project

Award Identifier / Grant number: QJHKYZ[2018]291

  1. Author contributions: All the authors have accepted responsibility for the entire content of this submitted manuscript and approved submission.

  2. Research funding: This work was funded by Science and Technology Fund Project of Guizhou (NO. [2020]1Z023; NO. QKHJC[2019]1015), Guizhou Provincial Department of Education Youth Science and Technology Talents Growth Project (NO. QJHKYZ[2018]291).

  3. Conflict of interest statement: The authors declare no conflicts of interest regarding this article.

References

1. Dolomanov, O. V., Bourhis, L. J., Gildea, R. J., Howard, J. A. K., Puschmann, H. OLEX2: a complete structure solution, refinement and analysis program. J. Appl. Crystallogr. 2009, 42, 339–341; https://doi.org/10.1107/s0021889808042726.Search in Google Scholar

2. Sheldrick, G. M. SHELXTL – integrated space-group and crystal-structure determination. Acta Crystallogr. 2015, A71, 3–8; https://doi.org/10.1107/s2053273314026370.Search in Google Scholar PubMed PubMed Central

3. Sheldrick, G. M. Crystal structure refinement with SHELXL. Acta Crystallogr. 2015, C71, 3–8; https://doi.org/10.1107/s2053229614024218.Search in Google Scholar PubMed PubMed Central

4. Cawrse, B. M., Lapidus, R. S., Cooper, B., Choi, E. Y., Seley-Radtke, K. L. Anticancer properties of halogenated pyrrolo[3,2-d]pyrimidines with decreased toxicity via N5 substitution. ChemMedChem 2018, 13, 178–185; https://doi.org/10.1002/cmdc.201700641.Search in Google Scholar PubMed PubMed Central

5. Baillache, D. J., Unciti-Broceta, A. Recent developments in anticancer kinase inhibitors based on the pyrazolo[3,4-d]pyrimidine scaffold. RSC Med. Chem. 2020, 11, 1112–1135; https://doi.org/10.1039/d0md00227e.Search in Google Scholar PubMed PubMed Central

6. Wang, S., Li, Z.-R., Suo, F.-Z., Yuan, X.-H., Yu, B., Liu, H.-M. Synthesis, structure-activity relationship studies and biological characterization of new [1,2,4]triazolo[1,5–A]pyrimidine-based LSD1/KDM1A inhibitors. Eur. J. Med. Chem. 2019, 167, 388–401; https://doi.org/10.1016/j.ejmech.2019.02.039.Search in Google Scholar PubMed

7. Basyouni, W. M., Abbas, S. Y., El-Bayouki, K. A. M., Dawood, R. M., El Awady, M. K., Abdelhafez, T. H. Synthesis and antiviral screening of 2-(propylthio)-7-substituted-thiazolo[5,4-d]pyrimidines as anti-bovine viral diarrhea virus agents. J. Heterocycl. Chem. 2021, 58, 1766–1774; https://doi.org/10.1002/jhet.4307.Search in Google Scholar

8. Wang, R.-X., Du, S.-S., Wang, J.-R., Chu, Q.-R., Tang, C., Zhang, Z.-J., Yang, C.-J., He, Y.-H., Li, H.-X., Wu, T.-L., Liu, Y.-Q. Design, synthesis, and antifungal evaluation of luotonin a derivatives against phytopathogenic fungi. J. Agric. Food Chem. 2021, 69, 14467–14477; https://doi.org/10.1021/acs.jafc.1c04242.Search in Google Scholar PubMed

9. Fayed, E. A., Nosseir, E. S., Atef, A., El-Kalyoubi, S. A. In vitro antimicrobial evaluation and in silico studies of coumarin derivatives tagged with pyrano-pyridine and pyrano-pyrimidine moieties as DNA gyrase inhibitors. Mol. Divers. 2022, 26, 341–363; https://doi.org/10.1007/s11030-021-10224-4.Search in Google Scholar PubMed

10. Bassyouni, F., Tarek, M., Salama, A., Ibrahim, B., Salah El Dine, S., Yassin, N., Hassanein, A., Moharam, M., Abdel-Rehim, M. Promising antidiabetic and antimicrobial agents based on fused pyrimidine derivatives: molecular modeling and biological evaluation with histopathological effect. Molecules 2021, 26, 2370; https://doi.org/10.3390/molecules26082370.Search in Google Scholar PubMed PubMed Central

11. Pathan, N., Ali, P., Rahatgaonkar, A., Al-Mousa, K. An efficient one pot I2/DMSO mediated synthesis and molecular modeling of novel fused pyrimidine-chromone hybrids bearing potential antibacterial and antifungal pharmacophores sites. J. Heterocycl. Chem. 2021, 58, 1675–1689; https://doi.org/10.1002/jhet.4304.Search in Google Scholar

12. Preis, J., Schollmeyer, D., Detert, H. 5-Methyl-3-(3-methylphenyl)-7-phenyl-1,2,4-triazolo[4,3-c]pyrimidine. Acta Crystallogr. 2011, E67, o987.10.1107/S1600536811010683Search in Google Scholar PubMed PubMed Central

Received: 2022-07-15
Accepted: 2022-08-19
Published Online: 2022-08-30
Published in Print: 2022-12-16

© 2022 the author(s), published by De Gruyter, Berlin/Boston

This work is licensed under the Creative Commons Attribution 4.0 International License.

Articles in the same Issue

  1. Frontmatter
  2. New Crystal Structures
  3. The crystal structure of 1,5-bis(4-chlorophenyl)-3-(3-methylphenyl)pentane- 1,5-dione, C48H40Cl4O4
  4. Crystal structure of (bis(1,10-phenanthroline-κ 2 N,N′))-(3,5-dinitrosalicylato-κ 2 O,O′)nickel(II), C31H18N6NiO7
  5. Crystal structure of {N,N′-bis(4-fluoro-salicylaldehyde)-3,6-dioxa-1,8-diaminooctane-κ4 O,N,N′,O′}zinc(II), C20H20F2N2O4Zn
  6. [5-Bromo-2-(2-(dimethylamino)ethyliminomethyl)phenolato-κ3 N,N′,O]-isothiocyanato-nickel(II), C12H14BrN3NiOS
  7. Crystal structure of 9-bromo-4-(6-methoxypyridin-2-yl)-5,6-dihydrobenzo[h]quinazolin- 2-amine, C18H15BrN4O
  8. The crystal structure of imidazolium nitrate, C3H5O3N3
  9. Crystal structure of diiodido-bis(6,6′-dimethoxy-2,2′-(ethane-1,2-diylbis(nitrilomethanylylidene)) diphenolato)tricadmium(II), C36H36Cd3I2N4O8
  10. Crystal structure of [diaqua-bis(2-((1H-tetrazol-1-yl)methyl)-5-carboxy-1H-imidazole-4-carboxylato-κ2 N,O) manganese(II)] dihydrate, C14H18MnN12O12
  11. Crystal structure of Diaqua[5,5′-dicarboxy-2,2′-(propane-1,3-diyl)bis(1H-imidazole-4-carboxylato-k4 O,O′,N,N′)]iron(II), C13H14FeN4O10
  12. Crystal structure of poly[dimethanol-κ1O-(µ2-(E)-2-((2-oxidobenzylidene)amino)acetato)-(µ3-(E)-2-((2-oxidobenzylidene)amino)acetato)dicadmium(II)], C20H22Cd2N2O8
  13. Crystal structure of N 2,N 6-bis(2-(((E)-quinolin-8-ylmethylene)amino)phenyl)pyridine-2,6-dicarboxamide, C39H27N7O2
  14. An I 6 2 anion in the crystal structure of theophyllinium triiodide monohydrate, C7H11I3N4O3
  15. The crystal structure of poly[6,6′-oxybis(4-(pyridin-1-ium-1-yl)-1,3,5,2,4,6-trioxatriborinan-2-olate)], [B6O9](C5H5N)2
  16. The crystal structure of (carbonato κ2 O,O′)(2-oxopyridin-1(2H)-olato-κN)tris(trimethylphosphine)rhodium(III) water solvate, C15H33NO5P3Rh
  17. The crystal structure of dibromido-bis((RS)-2-(4-chlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)hexanenitrile-κ1 N)zinc(II), C30H34Br2Cl2N8Zn
  18. Synthesis and crystal structure of 3-(((7-hydroxy-3-(4-hydroxy-3,5-dinitrophenyl)-4-oxo-4H-chromen-8-yl)methyl)(nitroso)amino)propanoic acid, C19H14N4O11
  19. The crystal structure of 3-((4-chloro-N-(2-methoxyethyl)benzamido)methyl)phenyl methanesulfonate, C18H20ClNO5S
  20. Crystal structure of di([1,1′:3′,1″-terphenyl]-2′-yl)tellane, C36H26Te
  21. The crystal structure of diaqua-bis(pyrazolo[1,5-a]-pyrimidine-3-carboxylato-κ2 N,O)zinc(II), C14H12N6O6Zn
  22. Crystal structure of N′,N‴-((1E,2E)-1,2-diphenylethane-1,2-diylidene)bis(4-methylbenzohydrazide) – water – methanol (1/1/1), C31H32N4O4
  23. Crystal structure of 3-((2,4-dichlorobenzyl)thio)-5-methyl-7-(trifluoromethyl)-[1,2,4]triazolo [4,3-c]pyrimidine, C14H9Cl2F3N4S
  24. Crystal structure of 3,5,6,7-tetramethoxy-3′,4′-methylenedioxy-flavone, C20H18O8
  25. Crystal structure of catena-poly[(5,5′-dimethyl-2,2′-bipyridine-κ 2 N,N′)-(μ 3-hydrogen-1,1′,1″-(1,3,5-triazine-2,4,6-triyl)tris(piperidine-4-carboxylato)- κ 5 O:O,O′:O″,O‴)-cadmium(II)], C33H40CdN8O6
  26. The crystal structure of 3,5-bis(propan-2-yl)-1H-pyrazol-4-amine, C9H17N3
  27. Crystal structure of [(1,4,7,10-tetraoxacyclododecane-κ 4 O,O′,O″, O‴)-tris(nitrato-κ 2 O,O′)gadolinium(III)], C8H16N3O13Gd
  28. The crystal structure of 2,2′-((pyridine-2,6-diylbis(methylene))bis(sulfanediyl))-bis(4,5-dihydro-1H-imidazol-3-ium) bromide, C13H19Br2N5S2
  29. Crystal structure of E-2-chloro-N′-(1-(5-chloro-2-hydroxyphenyl)propylidene)benzohydrazide, C16H14Cl2N2O2
  30. Crystal structure of 3-(adamantan-1-yl)-4-methyl-5-{[(4-nitrophenyl)methyl]sulfanyl}-4H-1,2,4-triazole, C20H24N4O2S
  31. The crystal structure of dimethanol-κ1O-(5,10,15,20-tetrakis(4-nitrophenyl)porphyrin-21,23-diido-κ4 O,O′,O″,O′″)manganese(III) trans-dicyanido-κ1C-bis(acetylacetonato-κ2 O,O′)ruthenium(III), C58H46N10O14RuMn
  32. The crystal structure of nitroxyl-κ N-{hydridotris(3-trifluoromethyl-5-methylpyrazolyl-1-yl-κN 3)borato}nickel(II), C15H13BF9N7NiO
  33. The crystal structure of [(2,2′-bipyridine-κ2 N,N)-bis(6-phenylpyridine-2-carboxylato- κ2 N,O)nickel(II)] monohydrate, C34H26N4O5Ni
  34. The crystal structure of 5-(2-fluoro-3-methoxyphenyl)-1-(2-fluoro-6-(trifluoromethyl)benzyl)-6-methylpyrimidine-2,4(1H,3H)-dione, C20H15F5N2O3
  35. The crystal structure of ethyl 2,3,5-trifluoro-4-(4-oxo-3,4-dihydropyridin-1(2H)-yl)benzoate, C14H12F3NO3
  36. [2,2′-{Ethane-1,2-diylbis[(azanylylidene)methanylylidene]}bis(3-bromo-2-hydroxyphenyl)]iron(III) nitrate, C20H12Br2CuN2O2
  37. The crystal structure of 1-(2-iodophenyl)-4-phenyl-1H-1,2,3-triazole, C14H10IN3
  38. Synthesis and crystal structure of 2-(2-oxo-2-(thiophen-2-yl)ethyl)-4H-chromen-4-one, C15H10O3S
  39. {6,6′-((1E,1′E)-((2,2-dimethylpropane-1,3-diyl)bis(azaneylylidene))bis(methaneylylidene))bis(2-bromo-4-chlorophenolate)-κ4N,N′,O,O′}copper(II), C19H16Br2Cl2CuN2O2
  40. The crystal structure of N′-[bis(2-hydroxyphenyl)methylidene]pyridine-4-carbohydrazide, C19H15N3O3
  41. Crystal structure of 2-chloro-6-formylphenolato-κ2O,O′-(6,6′-(((2,2-dimethylpropane-1,3-diyl)bis(azaneylylidene))bis(methaneylylidene))bis(2-chlorophenolato)κ4 N,N,O,O′)cobalt(III), C26H22Cl3CoN2O4
  42. The crystal structure of tetrakis(6-phenylpyridine-2-carboxylate-κ 2 N,O)-bis(μ2-6-phenylpyridine-2-carboxylate-κ 2 O:O′)-bis(μ2-6-phenylpyridine-2-carboxylate-κ 3N,O:O)tetralead(II) C48H32N4O8Pb2
  43. The crystal structure of 3,7-dihydroxy-9-methoxy-4a-methyl-4aH-benzo[c] chromene-2,6-dione —dichloromethane (1/1), C16H14Cl2O6
  44. The crystal structure of (Z)-6-(((5-chloro-2-hydroxyphenyl)amino)methylene)- 4-nitrocyclohexa, C13H9ClN2O4
  45. Crystal structure of dichlorido-tetra((E)-(RS)-1-(2,4-dichlorophenyl)-4,4-dimethyl-2-(1,2,4-triazol-1-yl)pent-1-en-3-ol-κ1 N)zinc(II), C60H68O4N12Cl10Zn
  46. The crystal structure of 4-(2-bromoethoxy)-2-hydroxybenzaldehyde, C9H9BrO3
  47. The crystal structure of 5-azido-1-methyl-4-nitroimidazole, C4H4O2N6
  48. Crystal structure of dibromido-tetra((E)-(RS)-1-(2,4-dichlorophenyl)-4,4-dimethyl-2-(1,2,4-triazol-1-yl)pent-1-en-3-ol-κ 1 N)zinc(II), C60H68O4N12Br2Cl8Zn
  49. Crystal structure of tetrasodium-bis(μ 2-oxido)-hexafluoro-didioxo-molybdenum(V), Na2(Mo2O4F6)
  50. Crystal structure of (E)-N′-(2-chloro-6-hydroxybenzylidene)-4- hydroxybenzohydrazide-water (1/1), C14H13Cl1N2O4
  51. Crystal structure of (E)-N-(4-morpholinophenyl)-1-(quinolin-2-yl)methanimine, C20H19N3O
  52. The crystal structure of catena-poly[(1,10-phenanthroline-κ2 N,N′)-(μ3-2-hydroxybenzene-1,3-dicarboxylato-κ5 O,O′:O″,O‴:O‴)cadmium(II)], C20H12CdN2O5
  53. The crystal structure of 2,6-di-tert-butyl-4-(4-(methylthio)benzylidene)cyclohexa-2,5-dien-1-one, C22H28OS
  54. La3.65Mg30Sb1.07 as a disordered derivative of Th2Ni17-type structure
  55. Crystal structure of (E)-N-(4-morpholinophenyl)-1-(quinoxalin-2-yl)methanimine, C19H18N4O
  56. The crystal structure of 2,2′-(1,2-phenylenebis(methylene))bis(1,3-dimethylisothiouronium) bromide, C14H24Br2N4S2
  57. Crystal structure of tetraaqua-bis[4-(1H-1,2,4-triazol-1-yl)benzoato-κ1 N]zinc(II), C18H20ZnN6O8
  58. Crystal structure of bis(tricarbonyl)-{(S)-(tert-butoxycarbonyl)(1-methoxy-1-oxo-3-sulfido-k2 S:S′-propan-2-yl)amido-k2N:N′}diiron(I) (Fe—Fe), C15H15Fe2NO10S
  59. Crystal structure of (E)-3-((4-chlorophenyl)thio)-4-hydroxypent-3-en-2-one, C11H11ClO2S
  60. The crystal structure of (E)-3′,6′-bis(diethylamino)-2-((5-(diethylamino)-2-hydroxybenzylidene)amino)spiro[isoindoline-1,9′-xanthen]-3-one, C39H45N5O3
  61. The crystal structure of 2-(4-methoxynaphthalen-1-yl)-4H-chromen-4-one, C20H14O3
  62. The crystal structure of trans-dichlorido-(ethylenediamine-κ 2 N,N′)-bis(triphenylphosphine-κ 1 P)ruthenium(II), C38H38Cl2N2P2Ru
  63. The double polymeric chain of catena-poly[(μ2-6-bromopyridine-3-carboxylato-κ2 O,O′) (6-bromopyridine-3-carboxylato-κ2 O,O′) (μ2-1,2-bis(4-pyridyl)ethylene-κ2 N:N′)cobalt(II)], C24H16CoBr2N4O4
  64. The crystal structure of tert-butyl 2-(4-(12-bromo [2.2]paracyclophanyl)carbamoyl)pyrrolidine-1-carboxylate, C26H31BrN2O3
  65. The crystal structure of (Z)-2-(2,3-dimethoxybenzylidene)naphtho[1,2-b]furan-3(2H)-one, C21H16O4
  66. Crystal structure of 2-hydroxy-1-tosylindolin-3-yl- 2-naphthoate, C26H21N1S1O5
  67. The crystal structure of 1-methyl-N-(1-methyl-1H-imidazole-2-carbonyl)-1H-imidazole-2-carboxamide, C10H11N5O2
  68. The crystal structure of (E)-2-((5-bromo-2-hydroxybenzylidene)amino)-3′,6′-bis(ethylamino)-2′, 7′-dimethylspiro[isoindoline-1,9′-xanthen]-3-one, C33H31BrN4O3
  69. The crystal structure of dimethanol-5,15-diphenylporphyrin-21,23-diido-κ4 N,Nʹ,Nʺ,Nʹʺ-manganese(III) trans-dicyanido-bis(acetylacetonato-κ2O,Oʹ)ruthenium(III), C46H42N6O6RuMn
  70. Crystal structure of 1,4,8,11-tetraazacyclotetradecane-1,8-diium bis(3,5-dicarboxybenzoate), C28H36N4O12
  71. Bifurcated halogen bonds in the crystal structure of 2,2′-bi(1,8-naphthyridine)—1,4-diiodotetrafluorobenzene (1/1), C22H10F4I2N4
Downloaded on 25.3.2026 from https://www.degruyterbrill.com/document/doi/10.1515/ncrs-2022-0360/html
Scroll to top button